Dr. Euna Cho is a Director at Bionoxx Inc., a leading biotechnology company pioneering discoveries in functional neutrophil diversification and its impact on immuno-oncology. With over 10 years of experience in the industry for cell and gene therapy, Dr. Cho 's leadership has been instrumental in ensuring the efficient submission of investigational new drug application, securing USFDA acceptance for a first-in-human study evaluating mOTS-400, a novel immunomodulatory virotherapy for overcoming ICI resistance. Dr. Cho leverages her years of experience in project management and regulatory affairs to also drive the development of genetically modified autologous cell therapy and innovative neutrophil-targeted therapies. At BIO US, Dr. Cho will be presenting on immunomodulatory treatments based on the detection of disrupted functional immune states focusing on circulating neutrophils. Her presentation will delve into Bionoxx's latest advancements in immuno-oncology and its potential to overcome current challenges with ICI-resistance as well as exciting results in immune-related diseases. Dr. Cho is a passionate advocate for harnessing immunomodulatory strategies targeting the impaired neutrophil dynamics in cancer treatment and is excited to share Bionoxx's progress in this transformative field.